Free Trial
NASDAQ:LABT

Lakewood-Amedex Biotherapeutics Q1 2026 Earnings Results & Report

Lakewood-Amedex Biotherapeutics logo
$0.28 0.00 (0.00%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$0.28 0.00 (-0.85%)
As of 11/13/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Lakewood-Amedex Biotherapeutics reported Q1 2026 earnings on May 22, 2026. The company reported EPS of -$2.00.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
After Market Closes
Conference Call
8:00 AM ET

Lakewood-Amedex Biotherapeutics EPS Results

Actual EPS
-$2.00
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Lakewood-Amedex Biotherapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Earnings Documents

Lakewood-Amedex Biotherapeutics Q1 2026 Earnings FAQ

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) reported earnings of -$2.00 per share for Q1 2026. The report was announced on Friday, May 22, 2026.

Lakewood-Amedex Biotherapeutics Earnings Headlines

Executive Order 14241 Unleashes Trump’s New Dollar
A landmark executive order, 14241, is reportedly set to reshape how Americans use money starting this December. The agenda at the upcoming G20 Summit in Miami has shifted, and new research points to a major monetary announcement from President Trump. A new documentary breaks down what this shift could mean for savings, investments, and the assets tied to it.tc pixel
See More Lakewood-Amedex Biotherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Lakewood-Amedex Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lakewood-Amedex Biotherapeutics and other key companies, straight to your email.

About Lakewood-Amedex Biotherapeutics

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT), Inc. is a biotechnology company focused on the research and development of anti-infective therapies. Its work centers on developing treatments designed to address infections caused by bacteria and other pathogens.

The company’s activities are primarily directed toward advancing a pipeline of investigational therapeutic candidates rather than selling a broad portfolio of marketed products. Its development programs have focused on potential applications in human health, including treatments for localized and systemic infections.

Publicly available information about Lakewood-Amedex Biotherapeutics’ current product pipeline, commercial operations, geographic reach, and leadership is limited. The company should therefore be regarded primarily as a development-stage biotechnology enterprise.

View Lakewood-Amedex Biotherapeutics Profile